AGP Pharmaceuticals: Major
Health Technology
Mkt Cap
58.0B
P/E (TTM)
15.46
EPS
13.34
ROE
24.55%
Div Yield
3.86%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 28.89B | 25.03B | 18.74B | 14.46B | 9.32B | |
| Cost of Goods Sold | -12.12B | -10.86B | -8.96B | -7.36B | -4.43B | |
| Gross Profit | 16.77B | 14.17B | 9.79B | 7.10B | 4.88B | |
| SG&A Expenses | -8.58B | -7.01B | -5.44B | -4.06B | -2.28B | |
| Research & Development | -38.66M | -105.51M | -46.66M | -17.68M | -13.97M | |
| Depreciation | -473.65M | -355.07M | -295.61M | -231.25M | -164.90M | |
| Other Operating Expense | -249.45M | -101.60M | -34.38M | -24.70M | -26.38M | |
| Total Operating Expense | -20.95B | -17.97B | -14.43B | -11.44B | -6.74B | |
| Operating Income (EBIT) | 7.94B | 7.06B | 4.32B | 3.02B | 2.58B | |
| Interest Income | 62.53M | 71.61M | 81.83M | 39.73M | 22.33M | |
| Interest Expense | -1.44B | -2.69B | -1.63B | -534.78M | -205.11M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | -35.76M | -31.09M | -153.31M | -94.38M | -108.41M | |
| Total Non-Operating Income | -1.42B | -2.65B | -1.70B | -577.27M | -271.29M | |
| Pre-Tax Income | 6.52B | 4.41B | 2.62B | 2.44B | 2.31B | |
| Income Tax | -2.19B | -1.45B | -794.68M | -736.12M | -461.78M | |
| Minority Interest | -599.83M | -290.87M | -257.99M | -134.83M | -98.79M | |
| Net Income | 3.74B | 2.67B | 1.57B | 1.57B | 1.75B | |
| EBITDA | 8.43B | 7.44B | 4.64B | 3.27B | 2.76B | |
| EPS (Basic) | 13.34 | 9.53 | 5.59 | 5.61 | 6.24 | |
| EPS (Diluted) | 13.34 | 9.53 | 5.59 | 5.61 | 6.24 | |
| Gross Margin | 58.06% | 56.61% | 52.21% | 49.11% | 52.42% | |
| Operating Margin | 27.48% | 28.21% | 23.03% | 20.87% | 27.68% | |
| EBITDA Margin | 29.19% | 29.73% | 24.73% | 22.61% | 29.59% | |
| Pre-Tax Margin | 22.58% | 17.62% | 13.97% | 16.88% | 24.77% | |
| Net Margin | 12.93% | 10.66% | 8.35% | 10.86% | 18.75% |